i-Stat and Nova Biomedical settle patent suit:
This article was originally published in Clinica
i-Stat and Nova Biomedical have settled a patent infringement case brought by Nova relating to analysers and cartridges to determine hematocrit. The two companies agreed to dismiss the litigation with prejudice. i-Stat will pay Nova $6.5 million in cash and $3.5 million in a one-year secured promissory note. Nova will grant i-Stat a worldwide, non-exclusive licence to make and sell the devices by any method under the patent. i-Stat will also pay Nova a 4% royalty of the invoice price of products using the licensed method sold in the US from the beginning of this year.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.